Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Optimizing T-cell receptor avidity with somatic hypermutation.

Bassan D, Gozlan YM, Sharbi-Yunger A, Tzehoval E, Eisenbach L.

Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32612. [Epub ahead of print]

PMID:
31381134
2.

Comparative genomics of Lactobacillus sakei supports the development of starter strain combinations.

Eisenbach L, Geissler AJ, Ehrmann MA, Vogel RF.

Microbiol Res. 2019 Apr;221:1-9. doi: 10.1016/j.micres.2019.01.001. Epub 2019 Jan 14.

PMID:
30825936
3.

Lifestyle of Lactobacillus hordei isolated from water kefir based on genomic, proteomic and physiological characterization.

Xu D, Bechtner J, Behr J, Eisenbach L, Geißler AJ, Vogel RF.

Int J Food Microbiol. 2019 Feb 2;290:141-149. doi: 10.1016/j.ijfoodmicro.2018.10.004. Epub 2018 Oct 9.

PMID:
30340112
4.

A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.

Sharbi-Yunger A, Grees M, Cafri G, Bassan D, Eichmüller SB, Tzehoval E, Utikal J, Umansky V, Eisenbach L.

Int J Cancer. 2019 Feb 15;144(4):909-921. doi: 10.1002/ijc.31795. Epub 2018 Dec 5.

PMID:
30106470
5.

Comparative genomics of Lactobacillus curvatus enables prediction of traits relating to adaptation and strategies of assertiveness in sausage fermentation.

Eisenbach L, Janßen D, Ehrmann MA, Vogel RF.

Int J Food Microbiol. 2018 Dec 2;286:37-47. doi: 10.1016/j.ijfoodmicro.2018.06.025. Epub 2018 Jul 4.

PMID:
30031987
6.

Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.

Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, Eichmüller SB, Offringa R, Utikal J, Eisenbach L, Umansky V.

Oncoimmunology. 2018 Mar 26;7(7):e1445457. doi: 10.1080/2162402X.2018.1445457. eCollection 2018.

7.

Assertiveness of Lactobacillus sakei and Lactobacillus curvatus in a fermented sausage model.

Janßen D, Eisenbach L, Ehrmann MA, Vogel RF.

Int J Food Microbiol. 2018 Nov 20;285:188-197. doi: 10.1016/j.ijfoodmicro.2018.04.030. Epub 2018 Apr 20.

PMID:
29728282
8.

The anti-inflammatory IFITM genes ameliorate colitis and partially protect from tumorigenesis by changing immunity and microbiota.

Alteber Z, Sharbi-Yunger A, Pevsner-Fischer M, Blat D, Roitman L, Tzehoval E, Elinav E, Eisenbach L.

Immunol Cell Biol. 2018 Mar;96(3):284-297. doi: 10.1111/imcb.12000. Epub 2018 Jan 22.

PMID:
29356071
9.

Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer.

Zupančič E, Curato C, Kim JS, Yeini E, Porat Z, Viana AS, Globerson-Levin A, Waks T, Eshhar Z, Moreira JN, Satchi-Fainaro R, Eisenbach L, Jung S, Florindo HF.

Nanomedicine. 2018 Apr;14(3):835-847. doi: 10.1016/j.nano.2017.12.011. Epub 2018 Jan 3.

PMID:
29306001
10.

mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model.

Sharbi-Yunger A, Grees M, Tzehoval E, Utikal J, Umansky V, Eisenbach L.

Oncoimmunology. 2016 Apr 22;5(6):e1160183. doi: 10.1080/2162402X.2016.1160183. eCollection 2016 Jun.

11.

Tn7-Based Device for Calibrated Heterologous Gene Expression in Pseudomonas putida.

Zobel S, Benedetti I, Eisenbach L, de Lorenzo V, Wierckx N, Blank LM.

ACS Synth Biol. 2015 Dec 18;4(12):1341-51. doi: 10.1021/acssynbio.5b00058. Epub 2015 Jul 20.

PMID:
26133359
12.

mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.

Cafri G, Sharbi-Yunger A, Tzehoval E, Alteber Z, Gross T, Vadai E, Margalit A, Gross G, Eisenbach L.

Mol Ther. 2015 Aug;23(8):1391-1400. doi: 10.1038/mt.2015.90. Epub 2015 May 22.

13.

Body composition, hemodynamic, and biochemical parameters of young female normal-weight oligo-amenorrheic and eumenorrheic athletes and nonathletes.

Singhal V, de Lourdes Eguiguren M, Eisenbach L, Clarke H, Slattery M, Eddy K, Ackerman KE, Misra M.

Ann Nutr Metab. 2014;65(4):264-71. doi: 10.1159/000366024. Epub 2014 Oct 31.

14.

Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.

Alteber Z, Azulay M, Cafri G, Vadai E, Tzehoval E, Eisenbach L.

Cancer Immunol Immunother. 2014 Apr;63(4):369-80. doi: 10.1007/s00262-014-1520-4. Epub 2014 Jan 23.

PMID:
24452202
15.

Development of novel genetic cancer vaccines based on membrane-attached β2 microglobulin.

Cafri G, Margalit A, Tzehoval E, Eisenbach L, Gross G.

Ann N Y Acad Sci. 2013 Apr;1283:87-90. doi: 10.1111/nyas.12017. Epub 2013 Feb 6. Review.

PMID:
23387369
16.

Production of LacZ inducible T cell hybridoma specific for human and mouse gp100₂₅₋₃₃ peptides.

Cafri G, Sharbi-Yunger A, Tzehoval E, Eisenbach L.

PLoS One. 2013;8(2):e55583. doi: 10.1371/journal.pone.0055583. Epub 2013 Feb 1.

17.

Mouse dendritic cells pulsed with capsular polysaccharide induce resistance to lethal pneumococcal challenge: roles of T cells and B cells.

Cohen N, Margalit R, Pevsner-Fischer M, Yona S, Jung S, Eisenbach L, Cohen IR.

PLoS One. 2012;7(6):e39193. doi: 10.1371/journal.pone.0039193. Epub 2012 Jun 18.

18.

Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells.

Volovitz I, Marmor Y, Azulay M, Machlenkin A, Goldberger O, Mor F, Slavin S, Ram Z, Cohen IR, Eisenbach L.

J Immunol. 2011 Nov 15;187(10):5452-62. doi: 10.4049/jimmunol.1003946. Epub 2011 Oct 12.

19.

Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene.

Cafri G, Amram E, Rinott G, Koifman G, Fishman S, Keisari Y, Tzehoval E, Margalit A, Eisenbach L, Gross G.

Int Immunol. 2011 Jul;23(7):453-61. doi: 10.1093/intimm/dxr033. Epub 2011 Jun 7.

PMID:
21652516
20.

T cell vaccination induces the elimination of EAE effector T cells: analysis using GFP-transduced, encephalitogenic T cells.

Volovitz I, Marmor Y, Mor F, Flügel A, Odoardi F, Eisenbach L, Cohen IR.

J Autoimmun. 2010 Sep;35(2):135-44. doi: 10.1016/j.jaut.2010.05.003. Epub 2010 Jun 26.

PMID:
20580204
21.

T-cell seeding: neonatal transfer of anti-myelin basic protein T-cell lines renders Fischer rats susceptible later in life to the active induction of experimental autoimmune encephalitis.

Volovitz I, Mor F, Machlenkin A, Goldberger O, Marmor Y, Eisenbach L, Cohen IR.

Immunology. 2009 Sep;128(1):92-102. doi: 10.1111/j.1365-2567.2009.03074.x. Erratum in: Immunology. 2009 Nov;128(3):459. Machlenkin, Athur [corrected to Machlenkin, Arthur]; Cohen, Irun [corrected to Cohen, Irun R].

22.

A systems immunology approach to the host-tumor interaction: large-scale patterns of natural autoantibodies distinguish healthy and tumor-bearing mice.

Merbl Y, Itzchak R, Vider-Shalit T, Louzoun Y, Quintana FJ, Vadai E, Eisenbach L, Cohen IR.

PLoS One. 2009 Jun 25;4(6):e6053. doi: 10.1371/journal.pone.0006053.

23.

The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene.

Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L.

Int J Cancer. 2009 Dec 15;125(12):2810-9. doi: 10.1002/ijc.24669.

24.

Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.

Zhang QJ, Li XL, Wang D, Huang XC, Mathis JM, Duan WM, Knight D, Shi R, Glass J, Zhang DQ, Eisenbach L, Jefferies WA.

PLoS One. 2008 Aug 29;3(8):e3097. doi: 10.1371/journal.pone.0003097.

25.

Exuberated numbers of tumor-specific T cells result in tumor escape.

Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L.

Cancer Res. 2008 May 1;68(9):3450-7. doi: 10.1158/0008-5472.CAN-07-5006.

26.

Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs.

Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, Peretz T, Lotem M.

Cancer Res. 2008 Mar 15;68(6):2006-13. doi: 10.1158/0008-5472.CAN-07-3119.

27.

Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive.

Cohen N, Stolarsky-Bennun M, Amir-Kroll H, Margalit R, Nussbaum G, Cohen-Sfady M, Pevsner-Fischer M, Fridkin M, Bercovier H, Eisenbach L, Jung S, Cohen IR.

J Immunol. 2008 Feb 15;180(4):2409-18.

28.

'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E, Machlenkin A, Bar-Haim E, Do MS, Ahn IS, Fridkin M, Tzehoval E, Eisenbach L.

Br J Cancer. 2007 Dec 17;97(12):1655-63. Epub 2007 Dec 11.

29.

Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth.

Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenbach L, Canaani E.

Mol Cell Biol. 2007 Mar;27(5):1889-903. Epub 2006 Dec 18.

30.

Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.

Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L.

Cancer Immunol Immunother. 2007 Feb;56(2):217-26. Epub 2006 Jun 1.

PMID:
16738849
31.
32.

Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin.

Margalit A, Sheikhet HM, Carmi Y, Berko D, Tzehoval E, Eisenbach L, Gross G.

J Immunol. 2006 Jan 1;176(1):217-24.

33.

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.

Cancer Res. 2005 Jul 15;65(14):6435-42.

34.

Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.

Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L.

Clin Cancer Res. 2005 Jul 1;11(13):4955-61.

35.

Membrane-anchored beta 2-microglobulin stabilizes a highly receptive state of MHC class I molecules.

Berko D, Carmi Y, Cafri G, Ben-Zaken S, Sheikhet HM, Tzehoval E, Eisenbach L, Margalit A, Gross G.

J Immunol. 2005 Feb 15;174(4):2116-23.

36.

MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides.

Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, Brenner B, Vadai E, Mor O, Stein A, Lemonnier FA, Tzehoval E, Eisenbach L.

Br J Cancer. 2004 Jul 19;91(2):398-407.

37.

Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues.

Qimron U, Paul L, Bar-Haim E, Bloushtain N, Eisenbach L, Staats HF, Porgador A.

Vaccine. 2004 Mar 29;22(11-12):1390-4.

PMID:
15063561
38.

Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.

Lee SH, Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L.

Immunol Lett. 2004 Feb 15;91(2-3):119-26.

PMID:
15019279
39.

In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.

Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L.

Cancer Gene Ther. 2004 Mar;11(3):237-48.

PMID:
14739939
40.

The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients.

Markel G, Mussaffi H, Ling KL, Salio M, Gadola S, Steuer G, Blau H, Achdout H, de Miguel M, Gonen-Gross T, Hanna J, Arnon TI, Qimron U, Volovitz I, Eisenbach L, Blumberg RS, Porgador A, Cerundolo V, Mandelboim O.

Blood. 2004 Mar 1;103(5):1770-8. Epub 2003 Nov 6. Erratum in: Blood. 2015 Mar 19;125(12):2006.

41.
42.

Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines.

Margalit O, Eisenbach L, Amariglio N, Kaminski N, Harmelin A, Pfeffer R, Shohat M, Rechavi G, Berger R.

Br J Cancer. 2003 Jul 21;89(2):314-9.

43.

A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice.

Papo N, Shahar M, Eisenbach L, Shai Y.

J Biol Chem. 2003 Jun 6;278(23):21018-23. Epub 2003 Mar 19.

45.

Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice.

Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, Tirosh B, Klein T, Fridkin M, Lemonnier F, Tzehoval E, Eisenbach L.

J Clin Invest. 2002 Aug;110(4):453-62.

46.

CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.

Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O.

J Immunol. 2002 Mar 15;168(6):2803-10.

47.

Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens.

Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, Eisenbach L, Zavazava N, Admon A.

Eur J Immunol. 2002 Jan;32(1):213-22.

48.

Surrogate markers of antitumor responses: in vitro activation of T cells by autologous tumor peptides.

Zier K, Maddux JM, Johnson K, Sung M, Mandeli J, Eisenbach L, Schwartz M.

Clin Cancer Res. 2001 Mar;7(3 Suppl):818s-821s.

PMID:
11300478
49.

Antigenicity and immunogenicity of an intracellular delivery system of major histocompatibility complex class I epitopes that bypasses proteasome processing.

Tirosh B, Fridkin M, Tzehoval E, Vadai E, Lemonnier FA, Eisenbach L.

J Immunother. 2000 Nov-Dec;23(6):622-30.

PMID:
11186150
50.

Antitumor vaccination using peptide based vaccines.

Eisenbach L, Bar-Haim E, El-Shami K.

Immunol Lett. 2000 Sep 15;74(1):27-34. Review.

PMID:
10996624

Supplemental Content

Loading ...
Support Center